Breaking News

Tweet TWEET

Prima BioMed Conference Call to Discuss First Half of Fiscal Year 2013 Results

Prima BioMed Conference Call to Discuss First Half of Fiscal Year 2013 Results 
SYDNEY, AUSTRALIA -- (Marketwire) -- 03/04/13 --  Prima BioMed Ltd
(ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the
Company") today announced it will hold a conference call to discuss
its results for the first half of its fiscal year 2013, the period
from July 1 through December 31, 2012. The half year report was
previously released on the 28th of February 2013 and is available
through the Investor Relations section of the Company's website at
www.primabiomed.com.au. 
The call is scheduled for Thursday, the 7th of March 2013 at 9:00am
(Sydney local time). Conference call dial-in numbers are as follows: 
Australia Toll Free
 1 800 131 617 
Australia Alternate Toll Free
 1 800 838 758 
USA & Canada
 1 855 237 2970 
Germany
 0800 189 9369 
The call will also be audio webcast with additional supplemental
slides available via
http://services.choruscall.com/links/primabiomed130306.html. Before
launching the webcast, it is recommended to click on the link and
then on "test your systems configuration."  
A replay of the teleconference and webcast will be available through
Prima's website following the live event.  
About Prima BioMed
 Prima BioMed is a globally active biotechnology
company. As a leader in personalized bio-therapeutic products for
cancer, Prima is dedicated to leveraging its current technology and
expertise to develop innovative treatment options for patients and
maximize value to shareholders. Prima's lead product is CVac(TM), an
autologous dendritic cell product currently in clinical trials for
ovarian cancer patients who are in remission. 
For further information please contact: 
USA Investor/Media:
Ms. Jessica Brown 
Prima BioMed Ltd. 
+1 (919) 710-9061 
jessica.brown@primabiomed.com.au 
Australia Investor/Media:
Mr. James Moses 
Mandate Corporate 
+61 (0) 420 991 574 
james@mandatecorporate.com.au  
Europe Investor/Media:
Mr. Axel Muhlhaus 
edicto GmbH
+49 (0) 69 905505-52 
amuehlhaus@edicto.de